Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 1858-1867

  Norman, Mark H ^a   Liu, Longbin ^a   Lee, Matthew ^a   Xi, Ning ^a   Fellows, Ingrid ^a   D'Angelo, Noel D ^a   Dominguez, Celia ^a   Rex, Karen ^a   Bellon, Steven F ^a   Kim, Tae Seong ^a   Dussault, Isabelle ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTINEOPLASTIC AGENT; C MET INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLONE CARBOXAMIDE; PYRAZOLONE DERIVATIVE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG SELECTIVITY; HUMAN; IN VIVO STUDY; MALE; NONHUMAN; PHARMACOPHORE; PROTEIN BINDING; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; LIVER; MALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863241172     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201330u     Document Type: Article

References (25)

1. Cui, J. J. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications Expert Opin. Ther. Pat. 2007, 17, 1035-1045
2. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more Nature Rev. Mol. Cell Biol. 2003, 4, 915-925 and references cited therein.
3. Bean, J.; Brennan, C.; Shih, J.-Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W,-C.; Yu, C.-J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.-F.; Yang, P.-C.; Miller, V.; Ladanyi, M.; Yang, C.-H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 20932-20937
4. Dussault, I.; Bellon, S. F. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer Anti-Cancer Agents Med. Chem. 2009, 9, 221-229
5. For a discussion of alternative kinase binding modes see: Liu, Y; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nature Chem. Biol. 2006, 2 (7) 358-364
6. Simard, J. R.; Kluter, S; Grutter, C.; Getlik, M.; Rabiller, M.; Rode, H. B.; Rauh, D. A new screening assay for allosteric inhibitors of cSrc Nature Chem. Biol. 2009, 5 (6) 394-396
7. Albrecht, B. K.; Harmange, J.-C.; Bauer, D.; Berry, L.; Bode, C.; Boezio, A. A.; Chen, A.; Choquette, D.; Dussault, I.; Fridrich, C.; Hirai, S.; Hoffman, D.; Larrow, J. F.; Kaplan-Lefko, P.; Lin, J.; Lohman, J.; Long, A. M.; Moriguchi, J.; O'Connor, A.; Potashman, M. H.; Reese, M.; Rex, K.; Siegmund, A.; Shah, K.; Shimanovich, R.; Springer, S. K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Bellon, S. F. Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase J. Med. Chem. 2008, 51, 2879-2882
8. Bellon, S. F.; Kaplan-Lefko, P.; Yang, Y.; Zhang, Y.; Moriguchi, J.; Rex, K.; Johnson, C. W.; Rose, P. E.; Long, A. M.; O'Connor, A. B.; Gu, G.; Coxon, A.; Kim, T.-S.; Tasker, A.; Burgess, T. L.; Dussault, I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations J. Biol. Chem. 2008, 283, 2675-2683
9. Pyridone-based c-Met inhibitors selective over a number of kinases have been described: Schroeder, G. M.; An, Y.; Cai, Z.-W.; Chen, X.-T.; Clark, C.; Cornelius, L. A. M.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt, J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.; Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.; Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.; Wei, D.; Williams, D. K.; Zhang, Y.; Zhang, Y.; Fargnoli, J.; Borzilleri, R. M. Discovery of N -(4-(2-Amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily J. Med. Chem. 2009, 52, 1251-1254
10. Fujiwara, Y.; Senga, Y.; Nishitoba, T.; Osawa, T.; Miwa, A.; Nakamura, K. Preparation of quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor as antitumor agents. PTC Int. Appl. WO 2003000660A1, 2003, 441 pp.
11. Enzyme activities were generated internally.
12. As we have postulated previously, it might be useful to employ two types of c-Met inhibitors to treat c-Met-dependent tumors: very potent and selective class I inhibitors of wild-type c-Met and class II inhibitors that inhibit a wider range of c-Met mutations than those inhibited by class I molecules, thereby offering more treatment options for cancer patients. Dussault, I.; Bellon, S. F. c-Met inhibitors with different binding modes Cell Cycle 2008, 7 (9) 1157-1160
13. Berthou, S.; Aebersold, D. M.; Schmidt, L. S.; Stroka, D.; Heigl, C.; Streit, B.; Stalder, D.; Gruber, G.; Liang, C.; Howlett, A. R.; Candinas, D.; Greiner, R. H.; Lipson, K. E.; Zimmer, Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants Oncogene 2004, 23, 5387-5393
14. Buchanan, S. G.; Hendle, J.; Lee, P. S.; Smith, C. R.; Bounaud, P.-Y.; Jessen, K. A.; Tang, C. M.; Huser, N. H.; Felce, J. D.; Froning, K. J.; Peterman, M. C.; Aubol, B. E.; Gessert, S. F.; Sauder, J. M.; Schwinn, K. D.; Russell, M.; Rooney, I. A.; Adams, J.; Leon, B. C.; Do, T. H.; Blaney, J. M.; Sprengeler, P. A.; Thompson, D. A.; Smyth, L.; Pelletier, L. A.; Atwell, S.; Holme, K.; Wasserman, S. R.; Emtage, S.; Burley, S. K.; Reich, S. H. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo Mol. Cancer Ther. 2009, 8, 3181-3190
15. D'Angelo, N. D.; Bellon, S. F.; Booker, S. K.; Cheng, Y.; Coxon, A.; Dominguez, C.; Fellows, I.; Hoffman, D.; Hungate, R.; Kaplan-Lefko, P.; Lee, M. R.; Li, C.; Liu, L.; Rainbeau, E.; Reider, P. J.; Rex, K.; Siegmund, A.; Sun, Y.; Tasker, A. S.; Xi, N.; Xu, S.; Yang, Y.; Zhang, Y.; Burgess, T. L.; Dussault, I.; Kim, T.-S. Design, synthesis, and biological evaluation of potent c-Met inhibitors J. Med. Chem. 2008, 51, 5766-5779
16. Choquette, D.; Bellon, S.; Dussault, I.; Harmange, J.-C.; Kim, T.-S.; Rex, K.; Roveto, P. Pyridones: A New Class of Orally Bioavailable and Selective c-Met Inhibitors. Gordon Research Conference, Colby-Sawyer College, New London, NH, August 5-10, 2007.
17. Kim, K. S.; Zhang, L.; Schmidt, R.; Cai, Z.-W.; Wei, D.; Williams, D. K.; Lombardo, L. J.; Trainor, G. L.; Xie, D.; Zhang, Y.; An, Y.; Sack, J. S.; Tokarski, J. S.; Darienzo, C.; Kamath, A.; Marathe, P.; Zhang, Y.; Lippy, J.; Jeyaseelan, R., Sr.; Wautlet, B.; Henley, B.; Gullo-Brown, J.; Manne, V.; Hunt, J. T.; Fargnoli, J.; Borzilleri, R. M. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities J. Med. Chem. 2008, 51, 5330-5341
18. Singh, R. K.; Danishefsky, S. Homoconjugate addition of nucleophiles to cyclopropane-1,1-dicarboxylate derivatives: 2-oxo-1-phenyl-3- pyrrolidinecarboxylic acid Org. Synth. 1981, 60, 66-71
19. Kubo, K.; Shimizu, T.; Ohyama, S.-I.; Murooka, H.; Iwai, A.; Nakamura, K.; Hasegawa, K.; Kobayashi, Y.; Takahashi, N.; Takahashi, K.; Kato, S.; Izawa, T.; Isoe, T. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N -phenyl- N ′-{4-(4-quinolyloxy)phenyl}ureas J. Med. Chem. 2005, 48, 1359-1366
20. Menezes, R.; Smith, M. B. A mild and facile route to ω-amino esters Synth. Commun. 1988, 18, 1625-1636
21. Bal, B. S.; Childers, W. E., Jr.; Pinnick, H. W. Oxidation of α-,β-unsaturated aldehydes Tetrahedron 1981, 37, 2091-2096
22. Mannion, M. S.; Raeppel, S.; Claridge, S.; Zhou, N.; Saavedra, O.; Isakovic, L.; Zhan, L.; Gaudette, F.; Reappel, F.; Déziel, R.; Beaulieu, N.; Nguyen, H.; Chute, I.; Beaulieu, C.; Dupont, I.; Robert, M.-F.; Lefebvre, S.; Dubay, M.; Rahil, J.; Wang, J.; Ste-Croix, H.; Macleod, A. R.; Besterman, J. M.; Vaisburg, A. N -(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2- oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6552-6556
23. Raeppel, S.; Claridge, S.; Saavedra, O.; Gaudette, F.; Zhan, L.; Mannion, M.; Zhou, N.; Raeppel, F.; Granger, M.-C.; Isakovic, L.; Déziel, R.; Nguyen, H.; Beaulieu, N.; Beaulieu, C.; Dupont, I.; Robert, M.-F.; Lefebvre, S.; Dubay, M.; Rahil, J.; Wang, J.; Ste-Croix, H.; Macleod, A. R.; Besterman, J. M.; Vaisburg, A. N -(3-Fluoro-4-(2-arylthieno[3,2- b ]pyridin-7-yloxy)-2-oxo-3- phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 1323-1328
24. Schiering, N.; Knapp, S.; Marconi, M.; Flocco, M. M.; Cui, J.; Perego, R.; Rusconi, L.; Cristiani, C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12654-12659
25. Liu, L.; Norman, M. H.; Lee, M.; Xi, N.; Siegmund, A.; Boezio, A.; Booker, S.; Choquette, D.; D'Angelo, N. D.; Germain, J.; Yang, Y.; Zhang, Y.; Bellon, S. F.; Whittington, D. A.; Harmange, J.-C.; Dominguez, C.; Kim, T.-S.; Dussault, I. Structure-Based Design of Novel Class II c-Met Inhibitors: 2. SAR and Kinase Selectivity Profiles of the Pyrazolone Series. J. Med. Chem. 2012, DOI 10.1021/jm201331s.